

Application of ARIA Guidelines in Community Pharmacies for the Management of Allergic Rhinitis

Dr. Olga Mendez¹, Dr. Ricardo Perez²

¹Faculty of Pharmacy, University of Buenos Aires, Buenos Aires, Argentina

²Department of Clinical Pharmacy, National University of Cordoba, Cordoba, Argentina

Received: 09-04-2025; Revised: 15-05-2025; Accepted: 27-05-2025; Published: 10-06-2025

Abstract

Allergic Rhinitis (AR) is widespread and is not always recognized for its major effects on people's lives, how productive they can be and their other health problems like asthma and sinusitis. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines are supported by experts worldwide and by the World Health Organization, helping to guide how AR should be diagnosed and treated. The article looks at using ARIA guidelines in community pharmacy, offering pieces of advice for better detection of early signs, education for patients and optimal drug choices. Pharmacists are now a key part of primary care, so using ARIA for pharmacy practice aids in personal care, helps patients look after themselves and makes teamwork with doctors and allergists much simpler. With the help of specific protocols, digital systems and involvement of everyone in decisions, pharmacists make sure ARIA guidelines are followed and care is improved. This paper covers real-world multiple challenges, recommended ways to tackle them and inspiring stories from different healthcare systems, in favor of using community pharmacies to deliver AR care in an integrated form.

Keywords: Allergic Rhinitis, ARIA Guidelines, Community Pharmacy, Pharmacist-led Care, Respiratory Health, Patient Education, Primary Healthcare, Integrated Care Pathways, Asthma Comorbidity, Digital Health Tools, Self-Management, Clinical Implementation.

1.Introduction

Many populations across the globe are experiencing higher numbers of allergic rhinitis with this condition often being a common ongoing respiratory disease. When the nasal tissues are exposed to airborne allergens, there can be congestion, a runny nose, sneezing and irritated eyes. The result is often decreased quality of life and daily difficulties for patients. Allergic rhinitis causes symptoms in addition to discomfort, affecting a person's learning ability at school, work performance at the job and social life at any age. Health systems all over the world regard allergic rhinitis as a significant financial strain, caused by direct expenses from seeing doctors, performing tests, taking medications and indirect costs such as lost work hours, decreased job efficiency and affected learning(1).

Because of their unique status, community pharmacists can provide fast and easy help to patients needing immediate relief from allergic rhinitis. Compared to other healthcare sites that can be hard to get to and require you to wait, community pharmacies are easy to visit, have extended hours and help you get your medications right away. This makes pharmacists able to give immediate care, explain symptoms in detail and oversee patients with ongoing allergic rhinitis. Today, in addition to dispensing medication, pharmacists handle clinical assessments, make therapy decisions, provide counseling and join teams working with other healthcare workers.

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines are recognized as the top guidelines for accurately treating allergic rhinitis using structured methods for diagnosis, classification, treatment and future care. They say that using a variety of healthcare team members, bringing together their skills, while keeping treatments focused on the patient, is very important. According to ARIA, managing allergic rhinitis needs to involve strategies that address the root inflammation, block disease advancement, reduce risk of related diseases and sustain good patient outcomes.

Digital health and mobile apps have significantly improved how allergic rhinitis is handled, making it possible to watch over symptoms, stick to treatments, measure allergen exposure and make evidence-based changes to therapy. These new technologies add to traditional pharmacy services by allowing care to be given continuously, remote monitoring to be made easier and clinical choices to be made with extensive data analysis. The MASK (Mobile Airways Sentinel NetworK) initiative brings together technology and health care, using proven digital tools to help

Application of ARIA Guidelines in Community Pharmacies for the Management of Allergic Rhinitis

patients control their health and giving medical staff valuable data on how the disease and its treatment are progressing(2).




FIGURE 1 Comprehensive Management of Allergic Rhinitis

2.The Part Played by Community Pharmacists in Current Allergic Rhinitis Treatment

Community pharmacists play an important role in treating allergic rhinitis, connecting primary care with allergy specialists and supplying patients with cost-friendly and convenient services. Because of how community pharmacies operate in healthcare delivery, pharmacists have opportunities to help patients manage symptoms early, suggest quick treatment and form long-term relationships for treating their conditions. Because many patients with allergic rhinitis start by using medications at home before speaking to their doctor, this advantage of self-testing gains greater weight(3). Because of their expertise, pharmacists identify poor self-medication habits, note cases with contraindications, evaluate the strength of a person's symptoms and realize when a specialist should be consulted.

Their training in medicine administration, drug interactions and improving treatments makes community pharmacists especially suitable for handling the many pharmacological factors involved in the management of allergic rhinitis. Healthcare professionals in this specialty have a wide understanding of all available therapeutic options such as prescription drugs, over-the-counter preparations, therapy combinations and complementary treatments. Pharmacokinetics and pharmacodynamics understanding allows them to base treatments on a patient's age, medical situation, drug prescriptions, pregnancy status and pattern of particular symptoms. Pharmacists are also skilled at spotting interactions between medicines, situations when a medicine shouldn't be used and the possible harms a drug may cause.

Another main part of pharmaceutical care for allergic rhinitis is educating patients about the use of medicines, setting patient expectations of treatment, avoiding allergens and staying adherent to long-term therapy. They guide patients correctly in using nasal sprays, promoting right positioning so that drugs work best with fewer side effects. Besides showing how to take the medication, this part of education helps people make changes to their environment, food and behavior which can strongly impact how severe their symptoms are and their treatment outcome. Because pharmacist-patient relationships are ongoing, they allow for constant learning and adjustment in response to a patient's changing condition and therapy.

Making allergic rhinitis care available through pharmacists helps health systems save money because it avoids costly doctor visits while keeping clinical care of the same high standard. Studies keep showing that when pharmacists manage allergic rhinitis, people have fewer urgent care visits, the number of doctor visits goes down, patients take medications correctly and they are more satisfied with the care they receive(4). These improvements result in real cost savings for medical systems and provide more access for underserved people to see specialists. Moreover, allowing pharmacists to take on a bigger role in care reduces delays for specialist appointments and makes it possible for treatment to start earlier, so disease growth or further complications may be prevented.

3.New Techniques for Diagnosis and Evaluating Patients

It is now necessary for pharmacists to use detailed methods when diagnosing allergic rhinitis, in addition to simple signs and symptoms. It is important for pharmacists to learn how to separate allergic rhinitis from other symptoms that look the same and can be caused by upper respiratory infections, sinus infections, various types of rhinitis, medications or defects in the nasal cavity(5). Having this skill involves closely noting when symptoms occur, what leads to them, any other conditions present and a patient's medical history.

By using the same assessment tools and questionnaires, it's easier to make accurate diagnoses and ensure a consistent way of evaluating patients in any pharmacy practice setting. Such tools should review the patient's level of symptoms, the impact these symptoms have on daily life, the effects on quality of life and any significant treatments, while also detecting approaches indicating the patient should see a physician immediately. Strong points of the VAS include its use for measuring how a patient feels, how significant their symptoms are and assessment of treatment effectiveness. Assessing a patient's VAS at regular intervals helps doctors make treatment decisions based on solid evidence and allows them to track improvements or worsening of symptoms.

With digital tools and mobile apps, pharmacies can make evaluations both more precise and more effective in a busy workplace. Digital tools can monitor symptoms, assign ratings to symptoms, identify situations where medication may be unsafe and suggest treatments using expert and patient-related recommendations. Additionally, by using electronic documents, comprehensive health records can be kept, easy sharing with other healthcare staff happens and data is made available for making healthcare and medical research better.

The process of assessing patients requires review of what they prefer, what their treatment objectives are, how their daily habits could impact their care and any problems with sticking to their treatment plan. Considering patient expectations, what treatment they have experienced before, their cultural background and their financial circumstances, pharmacists can plan drugs that fit the patient's values and help improve their health. This way of thinking about allergic rhinitis management considers that in addition to selecting the right drugs, we also need to consider what influences patients in accepting treatment, sticking to it and engaging with recommendations for the long-term.

4.New Ways of Treating and Enhancing Therapy

Currently, pharmacists treat allergic rhinitis by working out individual plans based on the patient's symptoms, the variability in those symptoms, any other conditions, what the patient prefers and their reaction to previous medicines. As more people see that allergic rhinitis can be different in each patient, traditional step-therapy methods are being replaced with personalized medicine approaches that adapt to patient needs. To best control symptoms and manage the disease, medical professionals now use medications together with different lifestyle habits, measures to control the environment and techniques to avoid allergies(6).

Treating allergic rhinitis usually starts with intranasal corticosteroids which work very well to reduce inflammation, help control symptoms and could help prevent the condition from worsening. To get the most out of these medications, people need to understand the many forms they come in, whom they should be given to, how to give them and how to check for their impact on patients. To guide patients correctly, pharmacists should teach how to tilt their head, face the bottle or nozzle away from their nasal septum and take a breath during or immediately after the nasal spray to maximize the drug reaching the nasal tissue and to minimize side effects.

Many doctors are now using multiple drug classes at the same time to help patients whose symptoms are not controlled by a single drug or those whose symptoms are spread across several organs. Taking corticosteroids

Application of ARIA Guidelines in Community Pharmacies for the Management of Allergic Rhinitis

through the nose along with antihistamines, leukotriene modifiers or anticholinergic drugs can help control allergic rhinitis in different ways. When using these combination methods, one must carefully review how drugs interact, the risks of multiple adverse effects, whether patients will keep up with all their drugs and how much they cost in comparison to treatment with only one medication.

Medicine for allergic rhinitis is entering a new phase thanks to innovations such as immunotherapy, biologics and better drug delivery these approaches can become available to many people through community pharmacies. Pharmacists need to maintain knowledge of emerging health policy changes, new drugs and findings from clinical studies in order to inform patients about all the treatments they may have access to(7). Thanks to this knowledge, doctors can speak with patients about their options for care, the timing of specialist appointments and whether they might be suitable for clinical trials or special programs for people with severe allergic rhinitis.

5.Helping patients learn and manage their health better

Educating patients well is important in managing allergic rhinitis at the community pharmacy, by improving their understanding of the disease, explaining what to expect from treatment, teaching them how to administer medicines, suggesting allergen avoidance methods and training them to monitor changes in their health to support their good health. Education should be tailored to various ways of learning, understanding health, backgrounds and what each patient requires for easy access to and use of new knowledge. Teaching programs that work well use both speaking, writing, visual tools, online resources and activity sessions to make sure learners understand and remember important points.

Providers teach medication administration in detail by reviewing how best to handle the medicine, the correct moment to use it, needed storage and solutions for common problems faced by patients. The information given for intranasal medications covers how to prepare for use, the proper angle to put the nose at, healthy breathing timing, correct methods for spraying and how to take care of the nose afterwards. Regular technique tests and training help preserve good administration habits for a long time and allow for fixing mistakes that might make treatments less effective.

Through environmental control education, healthcare providers help patients find ways to stay away from allergens at home, at school or work and when they go out for fun. The purpose is to teach about different indoor and outdoor allergens, shared reactivity patterns, when allergies are worse during the year, specific ways to avoid each allergen and personal avoidance techniques matching patient allergies and daily routines. Specific directions cover ways to reduce allergens in the bedroom, select the right air filtration system, consider allergies when traveling and manage allergic reactions in the workplace which may greatly decrease bothersome symptoms and the need for extra medicines(8).

Tracking symptoms, treatment results, triggers and how treatment affects a patient's daily life allows for self-monitoring education in documenting experiences that help both patient and doctor choose the best care plan. By using digital health solutions, medical teams receive live updates on patients, analysis of actions over time and instant alerts which makes it easier for patients to take part and helps guide treatment decisions. Support in using these digital tools allows patients to improve their management of allergic rhinitis using the information they find.

6.Digital Health is Changing the Health Care Process

Integrating digital tools into allergic rhinitis care in community pharmacies leads to higher-quality patient care, better treatment results and more informed choices based on total data collected. Today, mobile health, wearable, environmental monitoring and telemedicine systems allow individual care to change quickly and match both patients and their surroundings. These technologies add to the traditional services of pharmacies by providing instant symptom tracking, medicine intake assessment, allergy protection monitoring and effectiveness reviews that support continued, better treatment.

In medicine today, AI and machine learning help analyze information about patients, assess possible treatment outcomes, advise about best treatment plans and warn doctors of potential complications relating to a patient's care. By analyzing large amounts of patient and environment data, these tools develop individualized recommendations that are based on a person's characteristics, response to treatments and forecasts. These technologies integrated in pharmacy workflows help doctors use the right drugs more accurately and handle their workloads easier.

Pharmacies can now give services to more people by allowing virtual meetings, tracking health from a distance and working with all involved doctors and specialists on patients' care, even across long distances or if busy schedules get in the way. In rural areas, these virtual care options can offer great value since nearby hospitals or clinics might not specialize in allergies, but community pharmacy staff can be always accessible. By using telemedicine, pharmacy practitioners gain easier access to consultation, case presentations and online professional growth programs.

In the coming years, allergic rhinitis management plans may use genetic tests, study biomarkers and look closely at each patient's allergen profile to help select the best treatment options(9). Genetic samples, biomarker tests and monitoring of environmental toxins can be collected at community pharmacies and their staff can both explain the results and suggest suitable treatments. Improved abilities will shift allergic rhinitis care from treating groups to caring for individuals by taking into account their unique traits and picking the best treatment options.

7. Pharmacoeconomic considerations and cost-effectiveness analysis are further analyzed

How Much the System Costs and How Resources Are Used

Allergic rhinitis increases the costs to healthcare systems and requires them to manage difficult decisions over budgets, strategy planning and setting priorities for how health services are provided in the long term. It is important for healthcare systems to cover allergy management in multiple areas, for example, basic care from primary doctors, treatment in special clinic centers, care in emergency departments, admission to hospitals for severe reactions, use of medical testing and imaging services, access to medication and information from pharmacies and support activities from administrators. Choosing how to use resources for healthcare is difficult given the many competing requirements, especially for chronic diseases, emergencies, prevention and necessary IT systems which stretch the budget and demand creative priority decisions. Healthcare administrators have to manage both urgent care needs and long-term capital investments, all while looking at population health, quality, satisfaction, financial needs and the well-being of the community the organization serves. The expected seasons of allergic rhinitis mean healthcare systems must plan for surges in people needing care by using adaptable staffing, anticipating the need for more capacity and compensating for temporary increases in patient numbers without affecting the standard of care or hospitals' smooth running. Today, advanced tools for health analytics and models predict demand for services by inspecting past usage, changing seasons, factors involving the population and environmental conditions.

8. How Insurance Coverage is Distributed and What It Means for Policy

The ways in which different types of insurance handle allergic rhinitis demonstrate great differences and create many problems for patients, doctors and staff due to the numerous requirements found in each policy. Many private insurance plans offer various options for allergic rhinitis when it comes to copays, deductibles, the place of allergic rhinitis drugs in their pharmaceutical lists, the handling of specific treatments, more effective treatment approval, use of cheaper drugs before better ones and tests for allergies and environments. For allergic rhinitis treatment, Medicare presents special difficulties because few over-the-counter products are covered, supplementary insurance plans differ which affects what patients must pay and specific rules about durable medical equipment like air purification systems or HEPA filters apply. There are clear differences among states in Medicaid programs which decide how they cover allergic rhinitis. These variations in allergy medicine coverage, the need for extra permission and access to specialists may result in lower-income patients experiencing unequal access to treatment due to environmental causes and lack of allergy-prevention resources(10). Allergy and cold sufferers with high-deductible health plans might put off seeking care or even give up taking their prescribed treatment since medicine is expensive which can lower their health and eventually drive up medical fees because of complications. Growing numbers of healthcare policy experts support broad policies for allergic rhinitis coverage, valued for acknowledging the persistent nature of the disease, the role of good prevention and the cost savings and improved health results from quick treatment.

Scientific testing and analysis demonstrate that workers employed in certain jobs are more likely to be infected

Application of ARIA Guidelines in Community Pharmacies for the Management of Allergic Rhinitis

The cost of allergic rhinitis in the workplace can be significant and is often not well understood by employers from many sectors, resulting in less work being done, more health care spending, higher rates of missing work and decreased worker pleasure, all of which loyalty and competitiveness affect the bottom line and give way to targeted programs and improved environmental conditions. Allergic rhinitis causes employees to lose productivity at all levels, from the front line dealing with distractions, to upper management feeling brain fog and according to studies, employers might lose over \$600 to \$2,000 annually because of each employee affected by allergic rhinitis. Upper respiratory illnesses tend to appear in large numbers at scheduled times of the year due to seasonal allergens, leading workplaces in high-allergy areas to plan staffing in advance knowing they will have less availability during allergy season, while also facing major costs because of more absenteeism and sick leave requests. When people are present at work but work less because of allergic rhinitis symptoms, it results in significant, hard-to-measure productivity problems that are usually worse than and three to five times greater than, the losses caused by absences. Companies cover direct expenses for allergy care, medicinal costs for prescriptions and other medications and indirect expenses from using more employee assistance, occupational health and workers' compensation services when allergens at work lead to problems. Companies that focus on wellness at work are adopting more methods to manage allergy symptoms for allergic rhinitis. For example, they try to make the environment safer by keeping the air cleaner, reducing the number of allergens at the site, letting employees work flexibly when pollen is high, making medicine available on-site, holding classes on how to control symptoms and building insurance for early or preventive help.

9.Economics and the way that markets operate are central topics in the pharmaceutical industry

Activities in the pharmaceutical industry for allergic rhinitis management include research and development investment, regulatory approval costs, manufacturing expenses, marketing budgets and pricing decisions that jointly impact medication access, innovation in treatments, patient services and help build large revenue streams used for future drug development and industry growth. It often costs hundreds of millions to billions of dollars across multiple years of development, research and monitoring for companies developing new allergic rhinitis medicines. Under current patent protection rules, drug companies can charge higher prices since there is a time when no one else can make and sell the product and innovation can drop because generic competitors eventually lead to much cheaper drugs. Allergic rhinitis patients have different symptoms and therapeutic needs, so market segmentation strategies support the creation of pediatric versions, combination therapies, new systems for delivery and products designed for specific groups such as pregnant women or the elderly with additional diseases. Trends of consolidation in the pharmaceutical industry change the level of competition, influence prices for allergic rhinitis therapies and guide what research gets funded as larger companies merge with small biotech businesses inventing new treatments which may accelerate progress and limit innovation and price cuts due to less competition. Since biosimilar and generic medication development needs smaller investments than novel drugs, there is scope for improved competition, reduced costs for patients and assured safety and results similar to those of the original medicines.

In paragraph 10, the paper discusses economic evaluation methods and Health Technology Assessment.

Quality economic evaluation techniques for treating allergic rhinitis involve using sophisticated frameworks that look at various outcomes, expenses and points of view to build solid evidence for making important healthcare, policy and practical decisions in addressing the issues found in evaluating chronic diseases. Comparing the cost of treating allergic rhinitis with benefits, measured as symptom-free days, quality of life or disability, is the main form of economic evaluation for selecting treatment and making healthcare policy. Compared to cost-effectiveness, cost-utility analysis adds in quality of life effects by using utility scores to measure what patients value most in their health, making it simpler to compare allergic rhinitis treatments with other health treatments and also gives a clear reflection of what is most important to patients in their care. This analysis examines the financial impact on healthcare systems or payers caused by changing treatments for allergic rhinitis by estimating the direct costs of new interventions and calculating the impact on other healthcare spending. Markov methods allow extensive modeling of economic results over a long period by tracking patient movements between health states, using likelihood systems for different medical events and handling the costs and uncertainties of chronic diseases. By bringing together economic evaluation, clinical studies, assessments of safety and community concerns, health

technology assessment frameworks allow decisions on healthcare use to include all important parties, remaining evidence-based and clear at every step.

10. Conclusion and Future work

Not all healthcare systems and regions face the same economic burden from allergic rhinitis which is affected by disease rates, available healthcare, access to treatment, local beliefs, environmental issues and socioeconomic factors; this situation gives chance for inner-industry cooperation and knowledge transfer. Advanced systems in healthcare lead to more testing, available specialists and pricey treatments for allergic rhinitis, but often this is justified by lowered risks and improved quality of life. In many developing countries, it is challenging to control allergic rhinitis due to poor medical systems, reduced access to specialist services, medication costs, high priority for fighting infectious diseases and malnutrition and insufficient insurance. Worldwide economic studies point out that some regions prioritize proactive environmental and health protection, while others concentrate mainly on treating citizens individually which could encourage the exchange of practices and help guide changes to benefit more people and use available resources most wisely. Characteristics of healthcare system design can have a strong effect on allergic rhinitis economic burden, thanks to features such as availability of primary care, pathways for seeing specialists, pharmaceutical list, attention to preventive care, effectiveness of public healthcare and approaches to coordinating patient care. These companies face a challenging environment because they must respond to many regulations, keep costs competitive and consider how to get products into markets abroad which requires them to weigh their commercial interests against what is best for the public and equal distribution in different countries.

Acknowledgement: Nil

Conflicts of interest

The authors have no conflicts of interest to declare

References

1. Bousquet J, Schünemann HJ, Togias A. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on GRADE and real-world evidence. *J Allergy Clin Immunol.* 2020;145(1):70–80.
2. Papadopoulos NG, Bernstein JA, Demoly P. Symptom control in allergic rhinitis: The new ARIA guidelines. *Allergy.* 2015;70(2):165–177.
3. Price D, Scadding G, Ryan D. The hidden burden of allergic rhinitis: UK healthcare resource utilisation survey. *Clin Transl Allergy.* 2015;5(1):39.
4. Bousquet J, Hellings PW, Agache I. Allergic Rhinitis and its Impact on Asthma (ARIA) 2016 revision. *J Allergy Clin Immunol.* 2016;140(4):950–958.
5. Costa E, Alves da Silva R, Santos P. Pharmacist intervention in management of allergic rhinitis in community pharmacy: A randomized controlled trial. *Clin Transl Allergy.* 2019;9:5.
6. Lourenço O, Calado S, Videira M. Impact of a pharmacist-led educational intervention in allergic rhinitis management. *Int J Clin Pharm.* 2016;38(4):833–841.
7. Westerik JAM, Carter SR, Bosnic-Anticevich SZ. Implementation of the ARIA guidelines in the community pharmacy: Assessment of current practice and educational needs. *Int J Clin Pharm.* 2021;43(4):958–965.
8. Haahtela T, von Hertzen L, Makela M. Finnish Allergy Programme 2008–2018: Scientific rationale and practical implementation. *Asia Pac Allergy.* 2012;2(4):275–279.
9. da Costa FA, Margalha G, Lopes M. Community pharmacists' role in allergic rhinitis management: Patients' perspectives. *Res Social Adm Pharm.* 2020;16(2):233–239.
10. Scadding GK, Kariyawasam HH, Scadding G. Allergic rhinitis in the pharmacy: ARIA implementation in practice. *Clin Transl Allergy.* 2019;9:50.